When to consider an inborn error of metabolism: an approach to paediatric neurometabolic disorders.
There is limited information available regarding the incidence and prevalence of IEM in South Africa. According to the current available published data, congenital hypothyroidism, (1) galactosaemia (2) and glutaric aciduria type 1 (3) are probably the top three treatable conditions. Mitochondrial disorders are an important group of metabolic errors, but remain difficult to diagnose. (4)
This article is intended as a brief guide to key features and available resources and does not deal with specific conditions and management issues.
A clinical approach to IEM with predominant neurological symptoms is discussed below.
Saudubray et al. defined three broad groups of IEM, summarised in Table I. (5), (6)
The patient's history is an important aspect in the identification of IEM. Key features in the history include:
* pre-eclampsia, haemolysis, abnormal liver functions, low platelets syndrome (HELLP), associated with disorders of fatty acid beta oxidation
* abnormal fetal movements
* family history
* siblings with unexplained encephalopathy
* progressive neurological disorders in family members
* other factors
* trigger factors, e.g. fasting, exercise, fever, intake of specific foods
* unexplained 'cerebral palsy'
The presentation of IEM changes at different ages; the most important features are summarised below:
* unexplained jaundic
Any unexplained neurological syndrome; static, intermittent or progressive with
Other organ involvement is common. The central nervous system (CNS) may be secondarily involved, as in galactosaemia.
Emergency or baseline investigations usually include:
* full blood count (FBC)
* acid base
* urea, creatinine
* glucose - if low, ketones, insulin, free fatty acids
* liver functions
* calcium, magnesium
* clotting profile
* urine-reducing substances.
Ammonia and lactate tests are not readily available but are important - contact the nearest tertiary centre if an infant remains acidotic.
Lactate may be falsely elevated in a struggling child or after using a tourniquet. It will be elevated if there is respiratory or hepatic compromise or circulatory disturbance.
Further investigations are best done in consultation with the laboratory or relevant specialist and may include:
* amino and organic acids on blood and urine
* acylcarnitine profiles
* enzyme analyses
* genetic studies
If advice is not readily available, or the patient is critically ill, heel-prick blood spots on filter paper can be dried, stored frozen (-20 [degrees]C) and used for future genetic and biochemical testing. Frozen urine, heparinised plasma and EDTA blood samples are useful for analysis. A small sterile skin biopsy in culture medium for fibroblast culture would complete the samples required for further testing.
There are potentially treatable disorders where early intervention, as for galactosaemia and hypothyroidism, is imperative. Broad neonatal screening is the only way to effectively diagnose these disorders prior to clinical presentation. It is performed routinely in many countries, excluding South Africa. Research is required to delineate which conditions would be most cost effective to screen for in South Africa.
Treatment principles include:
* Treat correctable factors immediately: hypoglycaemia, acidosis, seizures, cardiac failure, hyperammonaemia.
* Start a galactose-free formula if galactose is present in the urine.
* Supplementation with pyridoxine, folinic acid or biotin may be effective for early-onset drug-resistant seizures if there is an underlying defect in any of these pathways.
* Severe hyperammonaemia may require dialysis.
Specific treatment requires the establishment of a diagnosis and a personalised management plan devised by the neurometabolic team, including therapists and a dietician.
Role of the family practitioner
* Recognition of the at-risk infant and appropriate referral.
* Baseline screening.
* Chronic care assistance in liaison with the paediatrician and tertiary care centre or subspecialist.
Role of the paediatrician
* Will vary depending on special interests/ area of practice.
* Recognition of the at-risk infant, baseline +/- specific investigations and imaging.
* Stabilisation, management of acute crises in liaison with subspecialist/tertiary centre.
* Referral as necessary for dialysis, intensive care monitoring and subspecialist investigation.
* Chronic care in liaison with subspecialist.
* If an infant or child's presentation is atypical or unexplained, think of metabolic causes.
* Acute presentation often resembles sepsis, with refractory acidosis, recurrent vomiting, seizures, or altered level of consciousness.
* Chronic presentation is easy to miss and includes failure to thrive, developmental delay, epilepsy, 'cerebral palsy' (especially dystonic), and unexplained intellectual disability.
* Thoroughly check the family history.
* Investigate if there is no clear cause for severe disability.
* The clinical findings are the key to guiding investigations.
Dr George van der Watt, Head of Chemical Pathology, Red Cross Children's Hospital and executive member of the Southern African Metabolic Disease Group.
References and further reading available at www.cmej.org.za
Websites for further reading
Acute management protocols for known IEM (UK): http://www.bimdg.org.uk/
Human metabolome database: http://www.hmdb.ca. IEM protocols (USA): http://newenglandconsortium.org/
Newborn screening: North West University: http:// www.newbornscreening.co.za
North West University: http://www.pliem.co.za SSIEM: http://www.ssiem.org/webresources_inborn.asp
University of Cape Town Chemical Pathology and Metabolic laboratory: http://www.madlab.uct.ac.za
* Sepsis is the most common differential diagnosis
* IEM predisposes to sepsis
* Severe acidosis, hyperammonaemia, organ failure and cerebral oedema are clinical emergencies
Table I. Classification of inborn errors of metabolism according to Saudubray et al. (5), (6) Groups of Characteristics Treatment principles disorders Disorders of * Accumulation of * Remove the toxin intoxication toxic substances * Carnitine causes symptoms * Sodium benzoate * Aminoacidopathies after a symptom-free * Exchange (e.g. period transfusion phenylketonuria) * Fetal development * Dialysis * Organic acidurias is normal * Special diets (propionic * Acute symptoms: * Vitamins acidaemia) vomiting, lethargy, * Urea cycle (e.g. coma, stroke ornithine * Chronic: failureto transcarbamylase thrive, developmental deficiency) delay, cardiomyopathy * Sugar * Triggers include intolerances fever, intercurrent (galactosaemia) illness or intake * Metal of specific foods intoxication * Recurrent ketosis, (Menkes, Wilson acidosis and disease) hyperammonaemia Disorders of energy * The clinical * Avoid fasting metabolism spectrum is hypoglycaemia * Glycolysis influenced by the * Dietary * Glycogenosis accumulation modification * Gluconeogenesis of toxic compounds * Supplementation * Creatine and the lack of with co-factors such metabolism energy as co-enzyme Q10 and * Pentose phosphate * Multi-organ carnitine pathways presentation with * Management of * Fatty acid wide range of epilepsy oxidation defects symptoms and signs, * Specific enzyme * Mitochondrial e.g. seizures, replacement therapy disorders weakness, ptosis, (Pompe's) retinopathy, ataxia, * Monitor disease cardiomyopathy, liver progression and failure, support Fanconi's syndrome, where possible - sensorineural regular ECGs, deafness, endo- audiometry crine or haematological dysfunction * Onset at any age * Stepwise deterioration is typical; in children, there may be transient loss of skills following relatively minor infections * Lactic acidosis is not always present * Non/hypoketotic hypoglycaemia is classic; a suggestive history may include seizures after fasting; cramps post exercise or sudden infant death syndrome Disorders involving * Symptoms are * Enzyme replacement complex molecules permanent, in lysosomal Lysosomal progressive and disorders disorders unrelated * Chenodeoxycholic to food or acid in Peroxisomal intercurrent cerebroten-dinous disorders illness xanthomatosis Congenital disorder of glycosylation (CDG) Disorders of cholesterol synthesis
G T RIORDAN, MB ChB, FCPaed (SA), MMed (Paed Neuro)
Senior Specialist, Division of Paediatric Neurology, Red Cross War Memorial Children's Hospital, Cape Town
I SMUTS, BSc, MB ChB
Professor and Head of Paediatric Neurology, Steve Biko Academic Hospital, University of Pretoria
Correspondence to: Gill Riordan (gillian.riordan@ uct.ac.za)
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||More about ... Paediatric neurology|
|Author:||Riordan, G T; Smuts, I|
|Publication:||CME: Your SA Journal of CPD|
|Date:||Apr 1, 2011|
|Previous Article:||Cognitive and behavioural outcomes after traumatic brain injury in children: traumatic brain injury remains a leading cause of mortality and...|